aclidinium

Aclidinium is a long-acting inhaled anticholinergic bronchodilator used as maintenance therapy for chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It works by competitively and reversibly antagonizing muscarinic acetylcholine receptors (M1–M5), with its primary therapeutic effect mediated through inhibition of the M3 receptor on airway smooth muscle to induce bronchodilation. Aclidinium is not intended for acute relief of bronchospasm but rather for long-term management of COPD symptoms. The drug was approved in the United States in July 2012[1][3][5].

Brand names

Tudorza PressairBretaris GenuairEklira GenuairDuaklir GenuairDuaklirTudorza

Other names

aclidinium bromide